Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Dow
AstraZeneca
Harvard Business School
Express Scripts

Last Updated: October 1, 2022

NOCDURNA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Nocdurna patents expire, and what generic alternatives are available?

Nocdurna is a drug marketed by Ferring Pharms Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has one hundred and thirty-six patent family members in thirty-four countries.

The generic ingredient in NOCDURNA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nocdurna

A generic version of NOCDURNA was approved as desmopressin acetate by TEVA PHARMS USA on October 15th, 1997.

  Try it Free

US Patents and Regulatory Information for NOCDURNA

NOCDURNA is protected by eleven US patents.

Patents protecting NOCDURNA

Methods comprising desmopressin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION

Pharmaceutical formulations of desmopressin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods comprising desmopressin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION

Orodispersible dosage forms of desmopressin acetate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS

Pharmaceutical formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods of treatment using orodispersible desmopressin pharmaceutical formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS

Methods using desmopressin acetate in orodispersible form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS

Pharmaceutical formulations of desmopressin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS

Pharmaceutical formulations of desmopressin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS

Methods comprising desmopressin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS

Methods comprising desmopressin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NOCDURNA

See the table below for patents covering NOCDURNA around the world.

Country Patent Number Title Estimated Expiration
Japan 2013523628 See Plans and Pricing
Spain 2462465 See Plans and Pricing
Croatia P20180774 See Plans and Pricing
Japan 2019123739 夜間頻尿によって妨げられない睡眠の初期期間を増加させるための口腔内崩壊デスモプレシン (ORODISPERSIBLE DESMOPRESSIN FOR INCREASING INITIAL PERIOD OF SLEEP UNDISTURBED BY NOCTURIA) See Plans and Pricing
Luxembourg C00015 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NOCDURNA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2712622 122017000006 Germany See Plans and Pricing PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
2712622 C02712622/01 Switzerland See Plans and Pricing PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
3225249 2019C/520 Belgium See Plans and Pricing PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622 PA2017001 Lithuania See Plans and Pricing PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008
3225249 CA 2019 00023 Denmark See Plans and Pricing PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Colorcon
Dow
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.